Once the deal with Sanofi closes, the rare disease drug will become one of Recordati’s fastest forecast sellers.

Nine months after Bristol Myers Squibb’s LAG-3/PD-L1 combination Opdualag failed a Phase III trial in microsatellite stable metastatic colorectal cancer, Merck & Co's fixed-dose combo of favezelimab and Keytruda has suffered the same fate in the indication.

The European Medicines Agency has recommended the pan-EU approval of three rare disease drugs: Pfizer’s Hympavzi, Henlius Biotech’s Hetronify and ImmunoGen’s Elahere in addition to five other new medicines

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.